NeuBase Therapeutics, Inc.
NBSEDelisted May 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
Q4 2021 vs. Q3 2021
How the institutions holding NeuBase Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 48 | 46 | −2 |
| Shares | 10.1M | 11.2M | +1.11M (+11.0%) |
| Value | $36.6M | $31.6M | −$4.99M (−13.6%) |
New holders (6)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AIGH Capital Management LLC | 1,000,285 | $2.81M | 0.88% |
| Carnegie Mellon University | 939,412 | $2.64M | 1.06% |
| Worth Venture Partners, LLC | 229,253 | $644.0K | 0.32% |
| Citadel Advisors LLC | 29,528 | $83.0K | 0.00% |
| Fifth Lane Capital, LP | 20,000 | $56.0K | 0.03% |
| Heritage Wealth Advisors | 10,000 | $28.0K | 0.00% |
Sold out (8)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Gsa Capital Partners LLP | 351,178 | $1.27M |
| Stonepine Capital Management, LLC | 109,742 | $396.0K |
| Two Sigma Investments, LP | 85,796 | $310.0K |
| Ergoteles LLC | 74,552 | $269.0K |
| Marshall Wace, LLP | 50,310 | $182.0K |
| D. E. Shaw & Co., Inc. | 44,801 | $162.0K |
| HRT Financial LP | 27,056 | $97.0K |
| JPMorgan Chase & Co | 385 | $1.00K |